Altre lingue Centogene N.V.

Azioni

CNTG

NL0014040206

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,4889 ^USD	+1,88%		+7,24%	-59,26%

19/03	Centogene, Takeda Pharmaceutical collaborano per la diagnostica dei disturbi da accumulo lisosomiale	MT
19/03	Centogene N.V. annuncia l'estensione della partnership in corso con Takeda per continuare a fornire l'accesso ai test genetici per i pazienti con disturbi da accumulo lisosomiale	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Centogene Gets Nasdaq Noncompliance Notice	02/04
CENTOGENE Receives Nasdaq Non-Compliance Notice	02/04
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	19/03
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders	19/03
Centogene N.V. Announces the Extension of an Ongoing Partnership with Takeda to Continue Providing Access to Genetic Testing for Patients with Lysosomal Storage Disorders	19/03
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency	29/02
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing	28/02
CENTOGENE Explores Strategic Alternatives	28/02
Centogene Explores Strategic Alternatives	28/02
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration	25/01
Centogene N.V. and the Laboratory of Human Genetics of Infectious Diseases At Institut Imagine Announce Rare Disease Research Collaboration	25/01
CENTOGENE Receives French Research Tax Credit Accreditation	24/01
Centogene N.V. and The Michael J. Fox Foundation for Parkinson's Research Announces Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics	23/01
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics	23/01
CENTOGENE Announces Preliminary Full Year 2023 Revenue	18/01
Centogene N.V. Provides Earnings Guidance for the Full Year 2023	18/01
Centogene N : Minutes for Centogene EGM December 2023	19/12
CENTOGENE Announces Voting Results of Extraordinary General Meeting	19/12
Centogene N.V. Announces Changes to Supervisory Board	18/12
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone	13/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Centogene N.V.

Azioni

CNTG

NL0014040206

Altre lingue

Filtri